Related Experiment Video
Updated: Jun 22, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis
Junjun Wang1, Bing Hu, Yang Meng
1Department of Biochemistry, Jinling Hospital, Clinical School of Medical College, Nanjing University, 305#, East Zhong Shan Road, Nanjing, 210002, PR China. wangjj6@jlonline.com
Objectives:
To explore possible associations of malondialdehyde-modified low-density lipoprotein (MDA-LDL) and LDL-immune complexes (LDL-IC) with atherosclerosis in rheumatoid arthritis (RA).
Design And Methods:
Plasma MDA-LDL, LDL-IC levels and mechanisms of the changes were investigated in RA patients with or without coronary artery disease (CAD), simple CAD patients and control.
Results:
MDA-LDL and LDL-IC levels were found increased in all the studied patients, the RA patients with CAD exhibited the most significant changes. MDA-LDL levels were higher in the RA patients with CAD than those both in the simple RA and CAD patients. Multiple linear regression analysis showed that CAD, LDL-IC and erythrocyte sedimentation rate accounted for 36.5% of the variation in MDA-LDL levels; and age, activity, MDA-LDL and rheumatoid factors accounted for 34.5% of the variation in LDL-IC.
Conclusions:
High levels of MDA-LDL and LDL-IC are risk factors for increased risk of atherosclerosis in RA patients and are associated with inflammation.
Insights
High levels of malondialdehyde-modified low-density lipoprotein (MDA-LDL) and LDL-immune complexes (LDL-IC) are linked to atherosclerosis in rheumatoid arthritis (RA) patients. These markers are associated with inflammation and indicate increased cardiovascular risk.
Area of Science:
- Cardiovascular Research
- Rheumatology
- Biochemistry
Background:
- Rheumatoid arthritis (RA) is associated with an increased risk of atherosclerosis.
- The specific roles of modified lipoproteins in RA-related cardiovascular disease require further elucidation.
Purpose of the Study:
- To investigate the association between malondialdehyde-modified low-density lipoprotein (MDA-LDL) and LDL-immune complexes (LDL-IC) with atherosclerosis in rheumatoid arthritis (RA) patients.
Main Methods:
- Plasma levels of MDA-LDL and LDL-IC were measured in RA patients with or without coronary artery disease (CAD), patients with simple CAD, and healthy controls.
- Statistical analyses, including multiple linear regression, were employed to identify factors influencing MDA-LDL and LDL-IC levels.
Main Results:
- MDA-LDL and LDL-IC levels were elevated in all patient groups, with the highest levels observed in RA patients who also had CAD.
- MDA-LDL levels were significantly higher in RA patients with CAD compared to those with RA alone or CAD alone.
- CAD, LDL-IC, and erythrocyte sedimentation rate explained 36.5% of the variation in MDA-LDL levels. Age, disease activity, MDA-LDL, and rheumatoid factors explained 34.5% of the variation in LDL-IC.
Conclusions:
- Elevated MDA-LDL and LDL-IC are significant risk factors for atherosclerosis in RA patients.
- These modified lipoproteins are associated with inflammation, contributing to the heightened cardiovascular risk observed in RA.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Inflammation
